Incyclix Bio, LLC

About Incyclix Bio, LLC

Incyclix Bio is a next-generation cell cycle control company focused on advancing precision treatments targeting aberrant proliferation in various cancers. Their mission is to develop novel therapeutics, with a lead compound, INX-315, a cyclin-dependent kinase 2 (CDK2) inhibitor in clinical development.

Products & Services

INX-315:A potent and selective cyclin-dependent kinase 2 (CDK2) inhibitor currently in clinical development for cancer treatment.

Specialties

Cyclin-dependent kinase (CDK) inhibitors Cell cycle control Precision cancer treatments CDK2 inhibition

Funding History

Debug: View Raw Funding Data

#	Type	Amount Fields	Date Fields	Investors
1	RT: Series B T: - FT: Series B	A: 5000000 MR: - FA: $5 million FAN: 5000000	D: 2026-04-08 FD: 2026-04-08	7 investors
2	RT: Series B Extension T: - FT: Series B Extension	A: 11250000 MR: - FA: $11.25 million FAN: 11250000	D: 2025-08-25 FD: 2025-08-25	4 investors

Series B Latest

2026-04-08

$5.0M

7 investors (Pro only)

Series B Extension 2025-08-25

$11.2M

View 1 more funding rounds with Pro

Unlock Full Funding History

Growth Metrics

+45%

Employee Growth

YoY

3.2x

Funding Growth

Last Round

12

Markets

Operating

10K+

Customers

Active

View 3 more growth metrics with Pro

Unlock All Metrics

Mock Up

Team & Leadership

P

Patrick Roberts

Chief Executive Officer, Co-Founder

J

Jay Strum

Chief Scientific Officer, Co-Founder

J

John Bisi

Senior Vice President of Research and Development, Co-Founder

K

Karen Makhuli

Vice President, Clinical Operations

A

Andrew Beelen

Vice President of Clinical Development

M

Max DeNies

Board Observer

View 6 more team members with Pro

Unlock Full Team Directory

Recent News

Incyclix Bio, LLC Announces New Product Launch

2 days ago

Company unveils innovative solution to transform the industry, expanding market reach and capabilities...

Leadership Team Expands with Industry Veteran

1 week ago

New executive brings 20+ years of experience to accelerate growth and strategic initiatives...

Company Recognized as Industry Leader

2 weeks ago

Receives prestigious award for innovation and customer satisfaction in competitive market...

Key Competitors

C1

Competitor Alpha

Series B · $50M raised

C2

Competitor Beta

Series C · $120M raised

C3

Competitor Gamma

Series A · $25M raised

C4

Competitor Delta

Seed · $10M raised